NuVinci® Cycling Advances Service Solution for Switzerland and France
Service for the French and Swiss markets to be handled by NuVinci Cycling's International Service Center
AMSTERDAM, NETHERLANDS / CEDAR PARK, TEXAS, Aug. 28, 2017 (GLOBE NEWSWIRE) --
Based on its mission "to move people better," NuVinci Cycling, a division of Fallbrook Technologies Inc., aims to get riders back on their bike as quickly as possible in case something goes wrong with their NuVinci Optimized(TM) bicycle, regardless of their location. With this in mind, and given the company's remarkable growth in France and Switzerland, NuVinci Cycling is advancing its service offering in those local markets to provide a better and more direct after-sales experience. Beginning September 1st, 2017, service for France and Switzerland will be managed by NuVinci Cycling's International Service Center in The Netherlands. The updates to the service structure brings multiple advantages, including optimized availability of spare parts, improved service team availability, a more direct connection to internal product experts, as well as a more effective service process.
Recently, the French market has seen a significant increase in its eBike sales, thus raising a new challenge for both OEMs and dealers operating in that market to offer fast and good quality services to their end-consumers. "To meet riders' expectations of having their bicycles running smoothly at any time, we now want to support partner OEMs by expanding the reach of our Service Center to now also include the French market," says Billy van den Ende, Sales Director at NuVinci Cycling. French dealers and OEMs can reach the Service Center in the Netherlands by e-mail: FRfirstname.lastname@example.org or phone: +33 97 073 13 34.
Service in Switzerland was previously handled by Ofelec AG. Since the demand for NuVinci Optimized bikes and eBikes has grown significantly since the relationship began, the need for an even more direct contact has arisen. As a result, retailers can only order spare parts through the website www.nuvinci.com/eurosales going forward. Dealers and manufacturers in Switzerland and Lichtenstein can contact NuVinci Cycling's Service Center by email: CHemail@example.com or phone: +41 43 508 55 97.
About NuVinci® Cycling
NuVinci Cycling, a division of Fallbrook Technologies Inc., moves people better throughits product portfolio of smooth, stepless, automatic, and integrated shifting products for bicycles and eBikes. The NuVinci technology incorporated in continuously variable transmissions (CVT) for bicycles has been providing the best rider experiences since 2006. NuVinci Optimized(TM) cycling products include the Nfinity(TM) and Harmony(TM) groupsets, utilizing the latest versions of the transmissions and controllers. Products from NuVinci Cycling, the leader in CVTs for bikes and eBIkes, are available globally in over 100 bicycle brands. For more information, visit www.nuvincicycling.com.
About Fallbrook Technologies
Fallbrook Technologies is the inventor of the revolutionary NuVinci® continuously variable planetary (CVP) technology, which enables performance and efficiencyimprovements for machines that use an engine, pump, motor, or geared transmissionsystem - including urban mobility vehicles, cars and trucks, industrial equipment, andmany other applications. Fallbrook has a unique collective development model andcommunity through which NuVinci technology licensees share enhancements, which adds to the value of the technology and accelerates product development. This approach enables forward-looking companies, who wish to create visionary new products with NuVinci technology, to move quickly from concept to market commercialization. Fallbrook is based in Cedar Park near Austin, Texas, USA and holds rights to over 800 patents and patent applications worldwide. For more information, visit www.fallbrooktech.com.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1f381fc7-b1c5-4682-a1fe-24c6268164ed
Anne Guethoff NuVinci Cycling + 49 160 92290159 Anne.Guethoff@nuvincicycling.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NuVinci Cycling via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Canacol Energy Ltd. Announces Private Offering of Senior Notes19.4.2018 16:23 | Pressmeddelande
CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE) (OTCQX:CNNEF) (BVC:CNEC) is pleased to announce that it intends, subject to market and other conditions, to offer senior unsecured notes (the "Notes") in a private placement to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), to non-U.S. persons in transactions outside the United States pursuant to Regulation S under the Securities Act and pursuant to certain prospectus exemptions in Canada (the "Offering"). The Notes will be fully and unconditionally guaranteed by certain subsidiaries of Canacol. The interest rate, redemption prices and other terms of the Notes are to be determined upon pricing of the Offering. Canacol intends to use the net proceeds from the Offering: (i) to repay the outstanding amounts borrowed under its credit facility; (ii) to pay fees and expenses of the O
FinancialForce Extends Professional Services Automation Leadership With its Spring 2018 Release19.4.2018 14:00 | Pressmeddelande
New features empower services organizations to run their businesses with greater predictability, assign best-fit resources at scale, and forecast projects with 360-degree insight. SAN FRANCISCO, April 19, 2018 (GLOBE NEWSWIRE) -- FinancialForce, the number one customer-centric ERP cloud vendor built on the Salesforce Platform, announced the availability of its latest version of Professional Services Automation, the highest customer-rated PSA solution for enterprise organizations. The Spring 2018 Release of PSA brings new functional capabilities to accelerate project staffing speed and accuracy; unify people and project data; enable better forecasting decisions; and enhance the overall user experience using the Salesforce Lightning framework. Fast, Accurate Resource Mapping With the Spring 2018 Release of PSA, project and resource managers can identify and assign best-fit resources with greater speed and accuracy. Through advanced skills filtering and search capabilities, including part
Cisco ACI Is Data Center Solution of Choice for Service Providers Worldwide19.4.2018 14:00 | Pressmeddelande
Service providers deliver new cloud services more quickly and offer superior customer experience with the help of Cisco Application Centric Infrastructure SAN JOSE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Providing secure, differentiated and rapidly delivered cloud services to customers is a crucial requirement for today's service providers. To meet cloud infrastructure demands, global service providers are increasingly turning to the Cisco® Application Centric Infrastructure (Cisco ACI(TM)) , the industry-leading software-defined networking (SDN) solution. Cisco ACI reduces operational costs with an automated, policy-based programmable architecture, while improving scalability and security. In addition, new Cisco ACI multi-site management capability helps service providers to connect and manage multiple geographically distributed Cisco ACI fabrics and to move and manage workloads with a single pane of glass. Cisco ACI is being deployed worldwide by service providers such as NTT Com
SpeeDx receives FDA clearance for Mycoplasma genitalium product19.4.2018 14:00 | Pressmeddelande
SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx's Resistance Plus ® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company's recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company - SpeeDx Pty Ltd - as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the Resistance Plus MG assay.* The Resistance Plus MG Positive Control kit contains synthetic DNA to simulate Mycoplasma genitalium, as well as five mutations known to confer resistance to macrolide antibiotics. Macrolide-resistant M. genitalium is a challenging sexually transmitted infection (STI), and global management guidelines are currently being adapted to deal with the rise in resistance. "This is an important product in our portfolio," said Elisa Mokany, Chief Technology Officer for SpeeDx. "M. genitalium is very difficult
Taconic Biosciences Launches New Inflammatory Bowel Disease Models19.4.2018 14:00 | Pressmeddelande
RENSSELAER, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, announces the launch of several new inflammatory bowel disease (IBD) animal models. As a fully-licensed provider of CRISPR/Cas9 gene editing technology, Taconic scientists knocked out the mouse Il10 gene to generate a spontaneous colitis mouse models. The new knockout models were created on Taconic's B6 (C57BL/6NTac) and BALB/c (BALB/cAnNTac) backgrounds, and are available at both the Excluded Flora (EF) and Germ Free (GF) health standards. Beyond the scientific benefits, Taconic is also making them easy to access by offering these models to commercial, contract research organization (CRO), and academic institutions under a simple label license. This represents a departure from the license requirements for Il10 knockouts from other animal model providers. "In order for animal models to drive drug discovery they need to be both
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 201819.4.2018 13:00 | Pressmeddelande
Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thursday, April 26, 2018. Merus' management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate developments. To participate in the call, please dial (877) 260-1463 (U.S.) or (706) 643-5907 (international) and reference conference ID 6184636. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived webcast replay will be available for 90 days. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeut
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum